The B-cell follicle in HIV infection: Barrier to a cure

Frontiers in Immunology

Volumn 9, Issue JAN, 2018, Pages

  Bronnimann, Matthew P ^a   Skinner, Pamela J ^b   Connick, Elizabeth ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

B cell follicle sanctuary; Cytotoxic T cell (CTL); Follicular dendritic cell; Gamma delta T cells; HIV cure research; NK cells; Regulatory T cells; T follicular helper cell subsets

Indexed keywords

B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; FOLLICULAR DENDRITIC CELL; GAMMA DELTA T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION SENSITIVITY; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; REVIEW; TFH CELL; VIRUS LATENCY;

EID: 85041133283     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00020     Document Type: Review

References (152)

1. Biberfeld P, Chayt KJ, Marselle LM, Biberfeld G, Gallo RC, Harper ME. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am J Pathol (1986) 125:436-42
2. Folkvord JM, Armon C, Connick E. Lymphoid follicles are sites of heightened human immunodeficiency virus type 1 (HIV-1) replication and reduced antiretroviral effector mechanisms. AIDS Res Hum Retroviruses (2005) 21:363-70. doi:10.1089/aid.2005.21.363
3. Connick E, Folkvord JM, Lind KT, Rakasz EG, Miles B, Wilson NA, et al. Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL. J Immunol (2014) 193:5613-25. doi:10.4049/jimmunol.1401161
4. Connick E, Mattila T, Folkvord JM, Schlichtemeier R, Meditz AL, Ray MG, et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol (2007) 178:6975-83. doi:10.4049/jimmunol.178.11.6975
5. Biberfeld P, Ost A, Porwit A, Sandstedt B, Pallesen G, Böttiger B, et al. Histopathology and immunohistology of HTLV-III/LAV related lymphadenopathy and AIDS. Acta Pathol Microbiol Immunol Scand A (1987) 95:47-65
6. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 340:1605-13. doi:10.1056/NEJM199905273402101
7. Deleage C, Turkbey B, Estes JD. Imaging lymphoid tissues in nonhuman primates to understand SIV pathogenesis and persistence. Curr Opin Virol (2016) 19:77-84. doi:10.1016/j.coviro.2016.07.002
8. Deleage C, Wietgrefe SW, Del Prete G, Morcock DR, Hao XP, Piatak M Jr, et al. Defining HIV and SIV reservoirs in lymphoid tissues. Pathog Immun (2016) 1:68-106. doi:10.20411/pai.v1i1.100
9. Tenner-Racz K, Stellbrink HJ, van Lunzen J, Schneider C, Jacobs JP, RaschdorffB, et al. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy. J Exp Med (1998) 187:949-59. doi:10.1084/jem.187.6.949
10. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A (2014) 111:2307-12. doi:10.1073/pnas.1318249111
11. Günthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol (1998) 72:2422-8
12. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 293:817-29. doi:10.1001/jama.293.7.817
13. Horiike M, Iwami S, Kodama M, Sato A, Watanabe Y, Yasui M, et al. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology (2012) 423:107-18. doi:10.1016/j.virol.2011.11.024
14. Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci U S A (2015) 112:E1126-34. doi:10.1073/pnas.1414926112
15. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity (2014) 41:529-42. doi:10.1016/j.immuni.2014.10.004
16. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med (2000) 192:1545-52. doi:10.1084/jem.192.11.1545
17. Yu D, Rao S, Tsai LM, Lee SK, He Y, Sutcliffe EL, et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity (2009) 31:457-68. doi:10.1016/j.immuni.2009.07.002
18. Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, et al. Bcl6 mediates the development of T follicular helper cells. Science (2009) 325:1001-5. doi:10.1126/science.1176676
19. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science (2009) 325:1006-10. doi:10.1126/science.1175870
20. Bryant VL, Ma CS, Avery DT, Li Y, Good KL, Corcoran LM, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol (2007) 179:8180-90. doi:10.4049/jimmunol.179.12.8180
21. Pène J, Gauchat JF, Lécart S, Drouet E, Guglielmi P, Boulay V, et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol (2004) 172:5154-7. doi:10.4049/jimmunol.172.9.5154
22. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med (2013) 210:143-56. doi:10.1084/jem.20121932
23. Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, Kranias G, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest (2012) 122:3271-80. doi:10.1172/JCI64314
24. Hufert FT, van Lunzen J, Janossy G, Bertram S, Schmitz J, Haller O, et al. Germinal centre CD4+ T cells are an important site of HIV replication in vivo. AIDS (1997) 11:849-57. doi:10.1097/00002030-199707000-00003
25. Kohler SL, Pham MN, Folkvord JM, Arends T, Miller SM, Miles B, et al. Germinal center T follicular helper cells are highly permissive to HIV-1 and alter their phenotype during virus replication. J Immunol (2016) 196:2711-22. doi:10.4049/jimmunol.1502174
26. Miller SM, Miles B, Guo K, Folkvord J, Meditz AL, McCarter MD, et al. Follicular regulatory T cells are highly permissive to R5-tropic HIV-1. J Virol (2017) 91:e430-417. doi:10.1128/JVI.00430-17
27. Amet T, Son YM, Jiang L, Cheon IS, Huang S, Gupta SK, et al. BCL6 represses antiviral resistance in follicular T helper cells. J Leukoc Biol (2017) 102:527-36. doi:10.1189/jlb.4A1216-513RR
28. Thacker TC, Zhou X, Estes JD, Jiang Y, Keele BF, Elton TS, et al. Follicular dendritic cells and human immunodeficiency virus type 1 transcription in CD4+ T cells. J Virol (2009) 83:150-8. doi:10.1128/JVI.01652-08
29. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med (2011) 17:983-8. doi:10.1038/nm.2426
30. Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, Rayner TF, et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med (2011) 17:975-82. doi:10.1038/nm.2425
31. Wollenberg I, Agua-Doce A, Hernández A, Almeida C, Oliveira VG, Faro J, et al. Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. J Immunol (2011) 187:4553-60. doi:10.4049/jimmunol.1101328
32. Miles B, Miller SM, Folkvord JM, Kimball A, Chamanian M, Meditz AL, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun (2015) 6:8608. doi:10.1038/ncomms9608
33. Haas MK, Levy DN, Folkvord JM, Connick E. Distinct patterns of Bcl-2 expression occur in R5-and X4-tropic HIV-1-producing lymphoid tissue cells infected ex vivo. AIDS Res Hum Retroviruses (2015) 31:298-304. doi:10.1089/aid.2014.0155
34. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 15:893-900. doi:10.1038/nm.1972
35. Petrovas C, Yamamoto T, Gerner MY, Boswell KL, Wloka K, Smith EC, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest (2012) 122:3281-94. doi:10.1172/JCI63039
36. Banga R, Procopio FA, Noto A, Pollakis G, Cavassini M, Ohmiti K, et al. PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat Med (2016) 22:754-61. doi:10.1038/nm.4113
37. McGary CS, Deleage C, Harper J, Micci L, Ribeiro SP, Paganini S, et al. CTLA-4+PD-1-memory CD4+ T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-infected rhesus macaques. Immunity (2017) 47:776-88.e5. doi:10.1016/j.immuni.2017.09.018
38. Pallikkuth S, Sharkey M, Babic DZ, Gupta S, Stone GW, Fischl MA, et al. Peripheral T follicular helper cells are the major HIV reservoir within central memory CD4 T cells in peripheral blood from chronically HIV-infected individuals on combination antiretroviral therapy. J Virol (2015) 90:2718-28. doi:10.1128/JVI.02883-15
39. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity (2011) 34:108-21. doi:10.1016/j.immuni.2010.12.012
40. Sage PT, Alvarez D, Godec J, von Andrian UH, Sharpe AH. Circulating T follicular regulatory and helper cells have memory-like properties. J Clin Invest (2014) 124:5191-204. doi:10.1172/JCI76861
41. Burton DR, Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol (2016) 34:635-59. doi:10.1146/annurev-immunol-041015-055515
42. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell (2013) 153:126-38. doi:10.1016/j.cell.2013.03.018
43. Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 39:758-69. doi:10.1016/j.immuni.2013.08.031
44. Havenar-Daughton C, Carnathan DG, Torrents de la Peña A, Pauthner M, Briney B, Reiss SM, et al. Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV Env trimer. Cell Rep (2016) 17:2195-209. doi:10.1016/j.celrep.2016.10.085
45. Yamamoto T, Lynch RM, Gautam R, Matus-Nicodemos R, Schmidt SD, Boswell KL, et al. Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection. Sci Transl Med (2015) 7:298ra120. doi:10.1126/scitranslmed.aab3964
46. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS (1994) 8:469-76. doi:10.1097/00002030-199404000-00008
47. Pallikkuth S, Parmigiani A, Silva SY, George VK, Fischl M, Pahwa R, et al. Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the 2009 H1N1/09 vaccine. Blood (2012) 120:985-93. doi:10.1182/blood-2011-12-396648
48. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 68:4650-5
49. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol (2008) 8:619-30. doi:10.1038/nri2357
50. Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 104:6776-81. doi:10.1073/pnas.0611244104
51. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 283:857-60. doi:10.1126/science.283.5403.857
52. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 189:991-8. doi:10.1084/jem.189.6.991
53. Tenner-Racz K, Racz P, Thomé C, Meyer CG, Anderson PJ, Schlossman SF, et al. Cytotoxic effector cell granules recognized by the monoclonal antibody TIA-1 are present in CD8+ lymphocytes in lymph nodes of human immunodeficiency virus-1-infected patients. Am J Pathol (1993) 142:1750-8
54. Bofill M, Gombert W, Borthwick NJ, Akbar AN, McLaughlin JE, Lee CA, et al. Presence of CD3+CD8+Bcl-2(low) lymphocytes undergoing apoptosis and activated macrophages in lymph nodes of HIV-1+ patients. Am J Pathol (1995) 146:1542-55
55. Devergne O, Peuchmaur M, Crevon MC, Trapani JA, Maillot MC, Galanaud P, et al. Activation of cytotoxic cells in hyperplastic lymph nodes from HIV-infected patients. AIDS (1991) 5:1071-9. doi:10.1097/00002030-199109000-00002
56. Piris MA, Rivas C, Morente M, Rubio C, Martin C, Olivia H. Persistent and generalized lymphadenopathy: a lesion of follicular dendritic cells? An immunohistologic and ultrastructural study. Am J Clin Pathol (1987) 87:716-24. doi:10.1093/ajcp/87.6.716
57. Reimann KA, Snyder GB, Chalifoux LV, Waite BC, Miller MD, Yamamoto H, et al. An activated CD8+ lymphocyte appears in lymph nodes of rhesus monkeys early after infection with simian immunodeficiency virus. J Clin Invest (1991) 88:1113-20. doi:10.1172/JCI115410
58. Brask S, Hager H, Pallesen G, Porwit A, Biberfeld P, Gerstoft J. Quantification of CD8-positive lymphocytes in lymph node follicles from HIV-infected male homosexuals and controls. Acta Pathol Microbiol Immunol Scand A (1987) 95:155-7
59. Tjernlund A, Zhu J, Laing K, Diem K, McDonald D, Vazquez J, et al. In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques. Retrovirology (2010) 7:12. doi:10.1186/1742-4690-7-12
60. Fukazawa Y, Lum R, Okoye AA, Park H, Matsuda K, Bae JY, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med (2015) 21:132-9. doi:10.1038/nm.3781
61. Leong YA, Chen Y, Ong HS, Wu D, Man K, Deleage C, et al. CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. Nat Immunol (2016) 17:1187-96. doi:10.1038/ni.3543
62. Li S, Folkvord JM, Rakasz EG, Abdelaal HM, WagstaffRK, Kovacs KJ, et al. Simian immunodeficiency virus-producing cells in follicles are partially suppressed by CD8+ cells in vivo. J Virol (2016) 90:11168-80. doi:10.1128/JVI.01332-16
63. Miles B, Miller SM, Folkvord JM, Levy DN, Rakasz EG, Skinner PJ, et al. Follicular regulatory CD8 T cells impair the germinal center response in SIV and ex vivo HIV infection. PLoS Pathog (2016) 12:e1005924. doi:10.1371/journal.ppat.1005924
64. Kim HJ, Verbinnen B, Tang X, Lu L, Cantor H. Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature (2010) 467:328-32. doi:10.1038/nature09370
65. Kim HJ, Wang X, Radfar S, Sproule TJ, Roopenian DC, Cantor H. CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice. Proc Natl Acad Sci U S A (2011) 108:2010-5. doi:10.1073/pnas.1018974108
66. He R, Hou S, Liu C, Zhang A, Bai Q, Han M, et al. Follicular CXCR5-expressing CD8(+) T cells curtail chronic viral infection. Nature (2016) 537:412-28. doi:10.1038/nature19317
67. Petrovas C, Ferrando-Martinez S, Gerner MY, Casazza JP, Pegu A, Deleage C, et al. Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Sci Transl Med (2017) 9:eaag2285. doi:10.1126/scitranslmed.aag2285
68. Hardtke S, Ohl L, Forster R. Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help. Blood (2005) 106:1924-31. doi:10.1182/blood-2004-11-4494
69. Heesters BA, Myers RC, Carroll MC. Follicular dendritic cells: dynamic antigen libraries. Nat Rev Immunol (2014) 14:495-504. doi:10.1038/nri3689
70. Gaufin T, Gautam R, Kasheta M, Ribeiro R, Ribka E, Barnes M, et al. Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. Blood (2009) 113:4250-61. doi:10.1182/blood-2008-09-177741
71. Keele BF, Tazi L, Gartner S, Liu Y, Burgon TB, Estes JD, et al. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol (2008) 82:5548-61. doi:10.1128/JVI.00124-08
72. Schmitz J, van Lunzen J, Tenner-Racz K, GrossschupffG, Racz P, Schmitz H, et al. Follicular dendritic cells retain HIV-1 particles on their plasma membrane, but are not productively infected in asymptomatic patients with follicular hyperplasia. J Immunol (1994) 153:1352-9
73. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science (1996) 274:985-9. doi:10.1126/science.274.5289.985
74. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 276:960-4. doi:10.1126/science.276.5314.960
75. Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, Keele BF, et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol (2001) 166:690-6. doi:10.4049/jimmunol.166.1.690
76. Heath SL, Tew JG, Tew JG, Szakal AK, Burton GF. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature (1995) 377:740-4. doi:10.1038/377740a0
77. Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, Moore JP, et al. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology (1992) 189:695-714. doi:10.1016/0042-6822(92)90593-E
78. Hart TK, Kirsh R, Ellens H, Sweet RW, Lambert DM, Petteway SR Jr, et al. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 88:2189-93. doi:10.1073/pnas.88.6.2189
79. Smith-Franklin BA, Keele BF, Tew JG, Gartner S, Szakal AK, Estes JD, et al. Follicular dendritic cells and the persistence of HIV infectivity: the role of antibodies and Fcgamma receptors. J Immunol (2002) 168:2408-14. doi:10.4049/jimmunol.168.5.2408
80. Heesters BA, Lindqvist M, VagefiPA, Scully EP, Schildberg FA, Altfeld M, et al. Follicular dendritic cells retain infectious HIV in cycling endosomes. PLoS Pathog (2015) 11:e1005285. doi:10.1371/journal.ppat.1005285
81. Orenstein JM. Hyperplastic lymphoid tissue in HIV/AIDS: an electron microscopic study. Ultrastruct Pathol (2008) 32:161-9. doi:10.1080/01913120802179408
82. Schmitz J, van Lunzen J, Tenner-Racz K, GrossschupffG, Racz P, Schmitz H, et al. Follicular dendritic cells (FDC) are not productively infected with HIV-1 in vivo. Adv Exp Med Biol (1994) 355:165-8. doi:10.1007/978-1-4615-2492-2_28
83. Sabri F, Prados A, Muñoz-Fernández R, Lantto R, Fernandez-Rubio P, Nasi A, et al. Impaired B cells survival upon production of inflammatory cytokines by HIV-1 exposed follicular dendritic cells. Retrovirology (2016) 13:61. doi:10.1186/s12977-016-0295-4
84. Chien YH, Meyer C, Bonneville M. gammadelta T cells: first line of defense and beyond. Annu Rev Immunol (2014) 32:121-55. doi:10.1146/annurev-immunol-032713-120216
85. Vantourout P, Hayday A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol (2013) 13:88-100. doi:10.1038/nri3384
86. Kabelitz D, Dechanet-Merville J. Editorial: 'recent advances in gamma/delta T cell biology: new ligands, new functions, and new translational perspectives'. Front Immunol (2015) 6:371. doi:10.3389/fimmu.2015.00371
87. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature (1995) 375:155-8. doi:10.1038/375155a0
88. Pauza CD, Poonia B, Li H, Cairo C, Chaudhry S. gammadelta T cells in HIV disease: past, present, and future. Front Immunol (2014) 5:687. doi:10.3389/fimmu.2014.00687
89. Soriano-Sarabia N, Archin NM, Bateson R, Dahl NP, Crooks AM, Kuruc JD, et al. Peripheral Vgamma9Vdelta2 T cells are a novel reservoir of latent HIV infection. PLoS Pathog (2015) 11:e1005201. doi:10.1371/journal.ppat.1005201
90. Wallace M, Bartz SR, Chang WL, Mackenzie DA, Pauza CD, Malkovsky M. Gamma delta T lymphocyte responses to HIV. Clin Exp Immunol (1996) 103:177-84. doi:10.1046/j.1365-2249.1996.d01-625.x
91. Poccia F, Agrati C, Martini F, Capobianchi MR, Wallace M, Malkovsky M. Antiviral reactivities of gammadelta T cells. Microbes Infect (2005) 7:518-28. doi:10.1016/j.micinf.2004.12.009
92. Tuero I, Venzon D, Robert-GuroffM. Mucosal and systemic gammadelta+ T cells associated with control of simian immunodeficiency virus infection. J Immunol (2016) 197:4686-95. doi:10.4049/jimmunol.1600579
93. Bansal RR, Mackay CR, Moser B, Eberl M. IL-21 enhances the potential of human gammadelta T cells to provide B-cell help. Eur J Immunol (2012) 42:110-9. doi:10.1002/eji.201142017
94. Caccamo N, Todaro M, La Manna MP, Sireci G, Stassi G, Dieli F. IL-21 regulates the differentiation of a human gammadelta T cell subset equipped with B cell helper activity. PLoS One (2012) 7:e41940. doi:10.1371/journal.pone.0041940
95. Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, Meraviglia S, et al. CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. J Immunol (2006) 177:5290-5. doi:10.4049/jimmunol.177.8.5290
96. Alter G, Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med (2009) 265:29-42. doi:10.1111/j.1365-2796.2008.02045.x
97. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature (1998) 391:397-401. doi:10.1038/34929
98. Luteijn R, Sciaranghella G, van Lunzen J, Nolting A, Dugast AS, Ghebremichael MS, et al. Early viral replication in lymph nodes provides HIV with a means by which to escape NK-cell-mediated control. Eur J Immunol (2011) 41:2729-40. doi:10.1002/eji.201040886
99. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood (2005) 106:3366-9. doi:10.1182/blood-2005-03-1100
100. Schafer JL, Li H, Evans TI, Estes JD, Reeves RK. Accumulation of cytotoxic CD16+ NK cells in simian immunodeficiency virus-infected lymph nodes associated with in situ differentiation and functional anergy. J Virol (2015) 89:6887-94. doi:10.1128/JVI.00660-15
101. Huot N, Jacquelin B, Garcia-Tellez T, Rascle P, Ploquin MJ, Madec Y, et al. Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys. Nat Med (2017) 23(11):1277-86. doi:10.1038/nm.4421
102. Beer B, Scherer J, zur Megede J, Norley S, Baier M, Kurth R. Lack of dichotomy between virus load of peripheral blood and lymph nodes during long-term simian immunodeficiency virus infection of African green monkeys. Virology (1996) 219:367-75. doi:10.1006/viro.1996.0262
103. Diop OM, Gueye A, Dias-Tavares M, Kornfeld C, Faye A, Ave P, et al. High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J Virol (2000) 74:7538-47. doi:10.1128/JVI.74.16.7538-7547.2000
104. Broussard SR, Staprans SI, White R, Whitehead EM, Feinberg MB, Allan JS. Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J Virol (2001) 75:2262-75. doi:10.1128/JVI.75.5.2262-2275.2001
105. Marban C, Forouzanfar F, Ait-Ammar A, Fahmi F, El Mekdad H, Daouad F, et al. Targeting the brain reservoirs: toward an HIV cure. Front Immunol (2016) 7:397. doi:10.3389/fimmu.2016.00397
106. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS (2011) 6:181-7. doi:10.1097/COH.0b013e328345a328
107. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 9:e1003211. doi:10.1371/journal.ppat.1003211
108. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS (2010) 24:1598-601. doi:10.1097/QAD.0b013e32833b61ba
109. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med (2004) 1:e36. doi:10.1371/journal.pmed.0010036
110. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 360:692-8. doi:10.1056/NEJMoa0802905
111. Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood (2011) 117:2791-9. doi:10.1182/blood-2010-09-309591
112. Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 9:e1003347. doi:10.1371/journal.ppat.1003347
113. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 161:319-27. doi:10.7326/M14-1027
114. Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol (2008) 20:14-25. doi:10.1016/j.smim.2007.12.001
115. Kinet-Denoel C, Heinen E, Radoux D, Simar LJ. Follicular dendritic cells in lymph nodes after x-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med (1982) 42:121-30. doi:10.1080/09553008214550991
116. Leibman RS, Riley JL. Engineering T cells to functionally cure HIV-1 infection. Mol Ther (2015) 23:1149-59. doi:10.1038/mt.2015.70
117. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med (1995) 1:330-6. doi:10.1038/nm0495-330
118. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, Corey L, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 5:34-41. doi:10.1038/4716
119. Lieberman J, Skolnik PR, Parkerson GR III, Fabry JA, Landry B, Bethel J, et al. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood (1997) 90:2196-206
120. Leibman RS, Richardson MW, Ellebrecht CT, Maldini CR, Glover JA, Secreto AJ, et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog (2017) 13:e1006613. doi:10.1371/journal.ppat.1006613
121. Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol (2015) 89:6685-94. doi:10.1128/JVI.00474-15
122. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, Micheli L, et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther (2005) 12:299-310. doi:10.1038/sj.gt.3302413
123. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther (2002) 5:788-97. doi:10.1006/mthe.2002.0611
124. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 4:132ra153. doi:10.1126/scitranslmed.3003761
125. Mylvaganam GH, Rios D, Abdelaal HM, Iyer S, Tharp G, Mavinger M, et al. Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection. Proc Natl Acad Sci U S A (2017) 114:1976-81. doi:10.1073/pnas.1621418114
126. Ayala VI, Deleage C, Trivett MT, Jain S, Coren LV, Breed MW, et al. CXCR5-dependent entry of CD8 T cells into rhesus macaque B-cell follicles achieved through T-cell engineering. J Virol (2017) 91:e2507-16. doi:10.1128/JVI.02507-16
127. Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog (2010) 6:e1000803. doi:10.1371/journal.ppat.1000803
128. Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog (2014) 10:e1003872. doi:10.1371/journal.ppat.1003872
129. Karpel ME, Boutwell CL, Allen TM. BLT humanized mice as a small animal model of HIV infection. Curr Opin Virol (2015) 13:75-80. doi:10.1016/j.coviro.2015.05.002
130. Bhiman JN, Lynch RM. Broadly neutralizing antibodies as treatment: effects on virus and immune system. Curr HIV/AIDS Rep (2017) 14:54-62. doi:10.1007/s11904-017-0352-1
131. Asokan M, Rudicell RS, Louder M, McKee K, O'Dell S, Stewart-Jones G, et al. Bispecific antibodies targeting different epitopes on the HIV-1 envelope exhibit broad and potent neutralization. J Virol (2015) 89:12501-12. doi:10.1128/JVI.02097-15
132. Pegu A, Asokan M, Wu L, Wang K, Hataye J, Casazza JP, et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nat Commun (2015) 6:8447. doi:10.1038/ncomms9447
133. Jiang G, Dandekar S. Targeting NF-kappaB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses (2015) 31:4-12. doi:10.1089/AID.2014.0199
134. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem (2004) 279:42008-17. doi:10.1074/jbc. M402124200
135. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog (2013) 9:e1003834. doi:10.1371/journal.ppat.1003834
136. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med (2014) 20:425-9. doi:10.1038/nm.3489
137. Marsden MD, Loy BA, Wu X, Ramirez CM, Schrier AJ, Murray D, et al. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell 'kick' and 'kill' in strategy for virus eradication. PLoS Pathog (2017) 13:e1006575. doi:10.1371/journal.ppat.1006575
138. Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, et al. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J Infect Dis (2015) 212:258-63. doi:10.1093/infdis/jiv022
139. Søgaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog (2015) 11:e1005142. doi:10.1371/journal.ppat.1005142
140. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 487:482-5. doi:10.1038/nature11286
141. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog (2014) 10:e1004473. doi:10.1371/journal.ppat.1004473
142. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV (2014) 1:e13-21. doi:10.1016/S2352-3018(14)70014-1
143. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med (2012) 13:291-6. doi:10.1111/j.1468-1293.2011.00975.x
144. Del Prete G. Novel approaches for the assessment of the in vivo residual virus pool and viral eradication strategies in SIV-infected rhesus macaques. 'Towards an HIV Cure' Pre-Conference Symposium, Washington, D.C., July 20-21. (2012)
145. Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 12:750-64. doi:10.1038/nrmicro3352
146. Cartwright EK, Spicer L, Smith SA, Lee D, Fast R, Paganini S, et al. CD8(+) lymphocytes are required for maintaining viral suppression in SIV-infected macaques treated with short-term antiretroviral therapy. Immunity (2016) 45:656-68. doi:10.1016/j.immuni.2016.08.018
147. Jones RB, Mueller S, O'Connor R, Rimpel K, Sloan DD, Karel D, et al. A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes. PLoS Pathog (2016) 12:e1005545. doi:10.1371/journal.ppat.1005545
148. Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog (2014) 10:e1004287. doi:10.1371/journal.ppat.1004287
149. Policicchio BB, Xu C, Brocca-Cofano E, Raehtz KD, He T, Ma D, et al. Multi-dose romidepsin reactivates replication competent SIV in post-antiretroviral rhesus macaque controllers. PLoS Pathog (2016) 12:e1005879. doi:10.1371/journal.ppat.1005879
150. Amy Ellis-Connell AB, Zarbock K, Barry G, Weiler A, Egan J, Jeng E, et al. ALT-803 decreases viral loads in ART-naive macaques. J Virol (2017). doi:10.1128/JVI.01748-17
151. Jiang JX, London E. Involvement of denaturation-like changes in Pseudomonas exotoxin A hydrophobicity and membrane penetration determined by characterization of pH and thermal transitions. Roles of two distinct conformationally altered states. J Biol Chem (1990) 265:8636-41
152. Shapira A, Benhar I. Toxin-based therapeutic approaches. Toxins (Basel) (2010) 2:2519-83. doi:10.3390/toxins2112519